Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin added to atorvastatin for diabetic nephropathy
IRCT20181118041689N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of melatonin and atorvastatin in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Urine albumin to creatinine ratio and Estimated glomerular filtration rate. Started Jan 2020; status: completed.
02
Drugs
melatoninatorvastatin
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20181118041689N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181118041689N1.